Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis

Xinshou Ouyang, Sheng Na Han, Ji Yuan Zhang, Balazs Tamas Nemeth, Pal Pacher, Dechun Feng, Ramon Bataller, Joaquin Cabezas, Peter Stärkel, Joan Caballeria, Rebecca Le Pine Pongratz, Shi Ying Cai, Bernd Schnabl, Rafaz Hoque, Yonglin Chen, Wei hong Yang, Irma Garcia Martinez, Fu Sheng Wang, Bin Gao, Natalia J TorokRichard Glenn Kibbey, Wajahat Zafar Mehal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Sterile inflammation after tissue damage is a ubiquitous response, yet it has the highest amplitude in the liver. This has major clinical consequences, for alcoholic and non-alcoholic steatohepatitis (ASH and NASH) account for the majority of liver disease in industrialized countries and both lack therapy. Requirements for sustained sterile inflammation include increased oxidative stress and activation of the HIF-1α signaling pathway. We demonstrate the ability of digoxin, a cardiac glycoside, to protect from liver inflammation and damage in ASH and NASH. Digoxin was effective in maintaining cellular redox homeostasis and suppressing HIF-1α pathway activation. A proteomic screen revealed that digoxin binds pyruvate kinase M2 (PKM2), and independently of PKM2 kinase activity results in chromatin remodeling and downregulation of HIF-1α transactivation. These data identify PKM2 as a mediator and therapeutic target for regulating liver sterile inflammation, and demonstrate a novel role for digoxin that can effectively protect the liver from ASH and NASH. Ouyang et al. show that the cardiac glycoside digoxin protects against liver disease by modulating the HIF-1α/oxidative stress pathway in sterile inflammation. Digoxin binds PKM2, limiting its availability to regulate transcription of pro-inflammatory genes. This study identifies a novel protective role for digoxin in alcoholic and non-alcoholic steatohepatitis.

Original languageEnglish (US)
Pages (from-to)339-350.e3
JournalCell Metabolism
Volume27
Issue number2
DOIs
StatePublished - Feb 6 2018

Fingerprint

Pyruvate Kinase
Digoxin
Fatty Liver
Transcriptional Activation
Inflammation
Cardiac Glycosides
Liver
Liver Diseases
Oxidative Stress
Chromatin Assembly and Disassembly
Developed Countries
Proteomics
Oxidation-Reduction
Homeostasis
Phosphotransferases
Down-Regulation
Therapeutics
Genes

Keywords

  • alcohol
  • digoxin
  • HIF-1α
  • liver
  • NASH
  • pyruvate kinase M2
  • ROS
  • steatohepatitis
  • sterile inflammation
  • therapy

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology

Cite this

Ouyang, X., Han, S. N., Zhang, J. Y., Nemeth, B. T., Pacher, P., Feng, D., ... Mehal, W. Z. (2018). Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metabolism, 27(2), 339-350.e3. https://doi.org/10.1016/j.cmet.2018.01.007

Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. / Ouyang, Xinshou; Han, Sheng Na; Zhang, Ji Yuan; Nemeth, Balazs Tamas; Pacher, Pal; Feng, Dechun; Bataller, Ramon; Cabezas, Joaquin; Stärkel, Peter; Caballeria, Joan; Pongratz, Rebecca Le Pine; Cai, Shi Ying; Schnabl, Bernd; Hoque, Rafaz; Chen, Yonglin; Yang, Wei hong; Martinez, Irma Garcia; Wang, Fu Sheng; Gao, Bin; Torok, Natalia J; Kibbey, Richard Glenn; Mehal, Wajahat Zafar.

In: Cell Metabolism, Vol. 27, No. 2, 06.02.2018, p. 339-350.e3.

Research output: Contribution to journalArticle

Ouyang, X, Han, SN, Zhang, JY, Nemeth, BT, Pacher, P, Feng, D, Bataller, R, Cabezas, J, Stärkel, P, Caballeria, J, Pongratz, RLP, Cai, SY, Schnabl, B, Hoque, R, Chen, Y, Yang, WH, Martinez, IG, Wang, FS, Gao, B, Torok, NJ, Kibbey, RG & Mehal, WZ 2018, 'Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis', Cell Metabolism, vol. 27, no. 2, pp. 339-350.e3. https://doi.org/10.1016/j.cmet.2018.01.007
Ouyang, Xinshou ; Han, Sheng Na ; Zhang, Ji Yuan ; Nemeth, Balazs Tamas ; Pacher, Pal ; Feng, Dechun ; Bataller, Ramon ; Cabezas, Joaquin ; Stärkel, Peter ; Caballeria, Joan ; Pongratz, Rebecca Le Pine ; Cai, Shi Ying ; Schnabl, Bernd ; Hoque, Rafaz ; Chen, Yonglin ; Yang, Wei hong ; Martinez, Irma Garcia ; Wang, Fu Sheng ; Gao, Bin ; Torok, Natalia J ; Kibbey, Richard Glenn ; Mehal, Wajahat Zafar. / Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. In: Cell Metabolism. 2018 ; Vol. 27, No. 2. pp. 339-350.e3.
@article{4c38ae693be34d6dbe56258d3fef5e82,
title = "Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis",
abstract = "Sterile inflammation after tissue damage is a ubiquitous response, yet it has the highest amplitude in the liver. This has major clinical consequences, for alcoholic and non-alcoholic steatohepatitis (ASH and NASH) account for the majority of liver disease in industrialized countries and both lack therapy. Requirements for sustained sterile inflammation include increased oxidative stress and activation of the HIF-1α signaling pathway. We demonstrate the ability of digoxin, a cardiac glycoside, to protect from liver inflammation and damage in ASH and NASH. Digoxin was effective in maintaining cellular redox homeostasis and suppressing HIF-1α pathway activation. A proteomic screen revealed that digoxin binds pyruvate kinase M2 (PKM2), and independently of PKM2 kinase activity results in chromatin remodeling and downregulation of HIF-1α transactivation. These data identify PKM2 as a mediator and therapeutic target for regulating liver sterile inflammation, and demonstrate a novel role for digoxin that can effectively protect the liver from ASH and NASH. Ouyang et al. show that the cardiac glycoside digoxin protects against liver disease by modulating the HIF-1α/oxidative stress pathway in sterile inflammation. Digoxin binds PKM2, limiting its availability to regulate transcription of pro-inflammatory genes. This study identifies a novel protective role for digoxin in alcoholic and non-alcoholic steatohepatitis.",
keywords = "alcohol, digoxin, HIF-1α, liver, NASH, pyruvate kinase M2, ROS, steatohepatitis, sterile inflammation, therapy",
author = "Xinshou Ouyang and Han, {Sheng Na} and Zhang, {Ji Yuan} and Nemeth, {Balazs Tamas} and Pal Pacher and Dechun Feng and Ramon Bataller and Joaquin Cabezas and Peter St{\"a}rkel and Joan Caballeria and Pongratz, {Rebecca Le Pine} and Cai, {Shi Ying} and Bernd Schnabl and Rafaz Hoque and Yonglin Chen and Yang, {Wei hong} and Martinez, {Irma Garcia} and Wang, {Fu Sheng} and Bin Gao and Torok, {Natalia J} and Kibbey, {Richard Glenn} and Mehal, {Wajahat Zafar}",
year = "2018",
month = "2",
day = "6",
doi = "10.1016/j.cmet.2018.01.007",
language = "English (US)",
volume = "27",
pages = "339--350.e3",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis

AU - Ouyang, Xinshou

AU - Han, Sheng Na

AU - Zhang, Ji Yuan

AU - Nemeth, Balazs Tamas

AU - Pacher, Pal

AU - Feng, Dechun

AU - Bataller, Ramon

AU - Cabezas, Joaquin

AU - Stärkel, Peter

AU - Caballeria, Joan

AU - Pongratz, Rebecca Le Pine

AU - Cai, Shi Ying

AU - Schnabl, Bernd

AU - Hoque, Rafaz

AU - Chen, Yonglin

AU - Yang, Wei hong

AU - Martinez, Irma Garcia

AU - Wang, Fu Sheng

AU - Gao, Bin

AU - Torok, Natalia J

AU - Kibbey, Richard Glenn

AU - Mehal, Wajahat Zafar

PY - 2018/2/6

Y1 - 2018/2/6

N2 - Sterile inflammation after tissue damage is a ubiquitous response, yet it has the highest amplitude in the liver. This has major clinical consequences, for alcoholic and non-alcoholic steatohepatitis (ASH and NASH) account for the majority of liver disease in industrialized countries and both lack therapy. Requirements for sustained sterile inflammation include increased oxidative stress and activation of the HIF-1α signaling pathway. We demonstrate the ability of digoxin, a cardiac glycoside, to protect from liver inflammation and damage in ASH and NASH. Digoxin was effective in maintaining cellular redox homeostasis and suppressing HIF-1α pathway activation. A proteomic screen revealed that digoxin binds pyruvate kinase M2 (PKM2), and independently of PKM2 kinase activity results in chromatin remodeling and downregulation of HIF-1α transactivation. These data identify PKM2 as a mediator and therapeutic target for regulating liver sterile inflammation, and demonstrate a novel role for digoxin that can effectively protect the liver from ASH and NASH. Ouyang et al. show that the cardiac glycoside digoxin protects against liver disease by modulating the HIF-1α/oxidative stress pathway in sterile inflammation. Digoxin binds PKM2, limiting its availability to regulate transcription of pro-inflammatory genes. This study identifies a novel protective role for digoxin in alcoholic and non-alcoholic steatohepatitis.

AB - Sterile inflammation after tissue damage is a ubiquitous response, yet it has the highest amplitude in the liver. This has major clinical consequences, for alcoholic and non-alcoholic steatohepatitis (ASH and NASH) account for the majority of liver disease in industrialized countries and both lack therapy. Requirements for sustained sterile inflammation include increased oxidative stress and activation of the HIF-1α signaling pathway. We demonstrate the ability of digoxin, a cardiac glycoside, to protect from liver inflammation and damage in ASH and NASH. Digoxin was effective in maintaining cellular redox homeostasis and suppressing HIF-1α pathway activation. A proteomic screen revealed that digoxin binds pyruvate kinase M2 (PKM2), and independently of PKM2 kinase activity results in chromatin remodeling and downregulation of HIF-1α transactivation. These data identify PKM2 as a mediator and therapeutic target for regulating liver sterile inflammation, and demonstrate a novel role for digoxin that can effectively protect the liver from ASH and NASH. Ouyang et al. show that the cardiac glycoside digoxin protects against liver disease by modulating the HIF-1α/oxidative stress pathway in sterile inflammation. Digoxin binds PKM2, limiting its availability to regulate transcription of pro-inflammatory genes. This study identifies a novel protective role for digoxin in alcoholic and non-alcoholic steatohepatitis.

KW - alcohol

KW - digoxin

KW - HIF-1α

KW - liver

KW - NASH

KW - pyruvate kinase M2

KW - ROS

KW - steatohepatitis

KW - sterile inflammation

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85044723075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044723075&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2018.01.007

DO - 10.1016/j.cmet.2018.01.007

M3 - Article

C2 - 29414684

AN - SCOPUS:85044723075

VL - 27

SP - 339-350.e3

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 2

ER -